Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection

Bone Marrow Transplantation

Volumn 19, Issue 2, 1997, Pages 129-133

  Prentice, H G ^a   Gluckman, E ^b   Powles, R L ^c   Ljungman, P ^d   Milpied, N J ^e   Camara, R ^f   Mandelli, F ^g   Kho, P ^h   Kennedy, L ^h   Bell, A R ^h  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b SAINT LOUIS HOSPITAL   (France)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e HÔTEL DIEU   (France)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g Istituto Mediterraneo di Ematologia   (Italy)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bone marrow transplant; Cytomegalovirus infection; High dose acyclovir; Prophylaxis

Indexed keywords

ACICLOVIR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL DISEASE; HLA MATCHING; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SURVIVAL TIME;

EID: 8044226594     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700498     Document Type: Article

References (8)

1. Bortin MM, Horowitz MM, Gale RP et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992; 268: 607-612.
2. Meyers JD, Reed EC, Shepp DH et al. Aciclovir for the prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl J Med 1988; 318: 70-75.
3. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749-753.
4. Talarico CL, Stanat SC, Biron KK. Evidence that HCMV-encoded UL97 contributes to the phosphorylation of acyclovir in HCMV-infected cells. Programme and abstracts from the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 4-7 October, 1994, Orlando, Florida. American Society for Microbiology: H65.
5. ™) produces acyclovir exposure comparable to that following intravenous acyclovir in allogeneic BMT patients. Programme and abstracts from 24th Annual Meeting of the European Group for Bone Marrow Transplantation 13-17 March 1994, Harrogate, UK. European Group for Bone Marrow Transplantation: 106.
6. Hägglund H, Boström L, Remberger M et al. Risk factor for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
7. Lönnqvist B, Palmblad J, Ljungman P et al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukemia in adults. Support Care Cancer 1993; 1: 139-144.
8. Griffiths PD, Grundy JE. Molecular biology and immunology of cytomegalovirus. Biochem J 1987; 241: 313-324.